

34. The use according to claim 31 wherein said
modified exendin or exendin agonist is a
modified exendin-4.

5

35. The method according to claim 32 which said
modified exendin or exendin agonist is a
modified exendin-4.

10

ABSTRACT

15

Novel modified exendins and exendin agonists having
an exendin or exendin agonist linked to one or more
polyethylene glycol polymers, for example, and related
formulations and dosages and methods of administration
thereof are provided. These modified exendins and exendin
agonists, compositions and methods are useful in treating
diabetes and conditions that would be benefited by
lowering plasma glucose or delaying and/or slowing gastric
emptying or inhibiting food intake.

20